Biofrontera Hit With Nasdaq Bid-Price Deficiency Notice, 180 Days to Reach $1.00
BFRI is trading near its 52-week low of $0.53 (0.0% above the low).
Summary
Biofrontera has received a Nasdaq notice that its stock traded under $1.00 for 30 consecutive business days, leaving until May 17, 2027 to regain compliance — a threshold roughly double today's $0.53 price.
Key Events · Legal and Risk Events · BFRI
-
Nasdaq Bid-Price Deficiency Notice
Nasdaq notified Biofrontera on November 16, 2026 that its common stock had closed below $1.00 per share for the previous 30 consecutive business days, a failure of Listing Rule 5550(a)(2).
-
180-Day Cure Window to May 17, 2027
Regaining compliance by May 17, 2027 requires a closing bid of at least $1.00 for a minimum of 10 consecutive business days — about double today's $0.53 price.
-
Reverse Split Likely Cure Path
Should the deficiency persist, Biofrontera may seek a second compliance period by meeting the market value of publicly held shares and other initial listing standards; the company has said it would consider a reverse stock split if necessary.
-
Layered on Going-Concern Doubt
The listing notice follows the Q3 report by a week; that report showed cash of $3.2 million and management's substantial going-concern doubt, so the cure effort competes with funding needs for the Ameluz launch.
Analysis · BFRI · Life Sciences
A Nasdaq deficiency letter dated November 16, 2026 has put Biofrontera on the clock: the stock closed below $1.00 for 30 straight business days. Trading continues for now, but the company has until May 17, 2027 to cure the deficiency, and doing so requires a $1.00 bid to hold for 10 consecutive business days. That is roughly double today's $0.53 price, making a reverse split the realistic path; Nasdaq rules permit a second compliance window only if the company also meets market-value and other initial listing standards. The notice lands on a balance sheet already carrying substantial going-concern doubt and just $3.2 million of cash as of the last quarterly report, so the listing fight competes directly with the funding needs of the Ameluz launch.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BFRI was trading at $0.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.5M. The 52-week trading range was $0.53 to $1.66. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.